Head to Head Comparison: BIO-key International (NASDAQ:BKYI) and GitLab (NASDAQ:GTLB)

BIO-key International (NASDAQ:BKYI – Get Free Report) and GitLab (NASDAQ:GTLB – Get Free Report) are both technology companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability and analyst recommendations.

Insider and Institutional Ownership

26.5% of BIO-key International shares are held by institutional investors. Comparatively, 95.0% of GitLab shares are held by institutional investors. 4.0% of BIO-key International shares are held by company insiders. Comparatively, 10.6% of GitLab shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Risk & Volatility

BIO-key International has a beta of 0.52, suggesting that its stock price is 48% less volatile than the S&P 500. Comparatively, GitLab has a beta of 0.96, suggesting that its stock price is 4% less volatile than the S&P 500.

Earnings & Valuation

This table compares BIO-key International and GitLab”s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
BIO-key International $6.09 million 0.71 -$7.16 million ($4.11) -0.52
GitLab $955.22 million 8.26 -$55.96 million ($0.32) -147.94

BIO-key International has higher earnings, but lower revenue than GitLab. GitLab is trading at a lower price-to-earnings ratio than BIO-key International, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares BIO-key International and GitLab’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
BIO-key International -50.01% -67.31% -40.28%
GitLab -4.99% -1.28% -0.77%

Analyst Recommendations

This is a summary of current ratings for BIO-key International and GitLab, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BIO-key International 1 1 0 0 1.50
GitLab 3 18 7 0 2.14

GitLab has a consensus target price of $52.50, suggesting a potential upside of 10.90%. Given GitLab’s stronger consensus rating and higher probable upside, analysts plainly believe GitLab is more favorable than BIO-key International.

Summary

GitLab beats BIO-key International on 12 of the 13 factors compared between the two stocks.

About BIO-key International

(Get Free Report)

BIO-key International, Inc. develops biometric identity and access management technology. Its solutions help organizations verify users and manage access to applications, systems and data, with fingerprint recognition as a core capability. The company’s offerings include PortalGuard, an identity and access management platform with features such as multifactor authentication and single sign-on, as well as biometric software and fingerprint readers. BIO-key also provides identity-bound biometric authentication designed to link access to a person’s unique characteristics.

About GitLab

(Get Free Report)

GitLab Inc. develops a software platform that helps organizations manage the software development lifecycle. Its tools support planning, source-code management, collaboration, continuous integration and delivery, security testing, and application monitoring. The GitLab platform brings these capabilities together in a single application, available as a cloud-hosted service or for customers to install and manage in their own environments. The company serves organizations in a range of industries and geographies, from individual developers to large enterprises.

Receive News & Ratings for BIO-key International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIO-key International and related companies with MarketBeat.com's FREE daily email newsletter.